Successful treatment of recurrent carotid in-stent restenosis and drug-eluting balloon failure with a coronary bioresorbable vascular scaffold: A case report  by Giordano, Arturo et al.
S
d
s
A
G
a
b
c
d
e
a
A
R
R
A
A
K
B
C
E
I
1
t
c
t
t
c
i
i
c
b
u
e
p
o
s
l
n
F
h
2
cCASE  REPORT  –  OPEN  ACCESS
International Journal of Surgery Case Reports 21 (2016) 78–82
Contents lists available at ScienceDirect
International  Journal  of  Surgery  Case  Reports
j ourna l h om epage: www.caserepor ts .com
uccessful  treatment  of  recurrent  carotid  in-stent  restenosis  and
rug-eluting  balloon  failure  with  a  coronary  bioresorbable  vascular
caffold:  A  case  report
rturo  Giordanoa,b, Paolo  Ferraroa,b, Nicola  Corcionea,b,  Stefano  Messinaa,b,
ennaro  Marescaa,b,  Enrico  Coscionic, Giuseppe  Biondi-Zoccaid,e,∗
Unità Operativa di Interventistica Cardiovascolare, Presidio Ospedaliero Pineta Grande, Castel Volturno, Italy
Unità Operativa di Emodinamica, Casa di Salute Santa Lucia, San Giuseppe Vesuviano, Italy
Division of Cardiac Surgery, San Giovanni di Dio e Ruggì D’Aragona Hospital, Salerno, Italy
Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 9 December 2015
eceived in revised form 23 February 2016
ccepted 24 February 2016
vailable online 27 February 2016
a  b  s  t  r  a  c  t
INTRODUCTION:  Carotid  in-stent  restenosis  is associated  with  substantial  risk  of recurrent  restenosis,
even  after  drug-eluting  balloon  usage.
PRESENTATION  OF  CASE:  We  hereby  report  the case  of  a patient  with  recurrent  carotid  in-stent  restenosis
and  drug-eluting  balloon  failure treated  with  a coronary  bioresorbable  vascular  scaffold,  achieving  aeywords:
ioresorbable vascular scaffold
arotid artery disease
ndovascular therapy
n-stent restenosis
satisfactory  acute  and  long-term  result,  as  disclosed  by duplex  ultrasound  scan  performed  more  than  1
year  after  the procedure.
DISCUSSION/CONCLUSION:  While  awaiting  for external  validation,  this  clinical  vignette  supports  expand-
ing the armamentarium  of endovascular  specialists  focusing  on  carotid  artery  disease,  while  providing
further  proof  of  the  safety  and  efﬁcacy  of  current  bioresorbable  vascular  scaffolds.
©  2016  The  Authors.  Published  by  Elsevier  Ltd.  on behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Carotid artery stenting has become an established alternative
o endarterectomy in the management of patients with signiﬁcant
arotid artery disease [1–4]. Despite remarkable improvements in
echnology, techniques, and ancillary medical therapy, complica-
ions and adverse events may  still occur. In particular, in-stent
arotid restenosis, while relatively uncommon, remains a challeng-
ng condition [2,5,6]. To date, a number of treatments for carotid
n-stent restenosis have been proposed, with heterogeneous out-
omes. The most favorable data, in terms of safety and efﬁcacy, have
een reported for drug-eluting balloons [2–9]. However, it remains
nclear how to address recurrent restenosis despite prior drug-
luting balloon dilation. We  hereby report the clinical vignette of a
atient with recurrent carotid in-stent restenosis despite prior use
f a drug-eluting balloon with a coronary bioresorbable vascular
caffold. This case may  expand the armamentarium of endovascu-
ar specialists focusing on carotid artery disease, while providing
∗ Corresponding author at: Department of Medico-Surgical Sciences and Biotech-
ologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy.
ax: +39 07731757254.
E-mail address: giuseppe.biondizoccai@uniroma1.it (G. Biondi-Zoccai).
ttp://dx.doi.org/10.1016/j.ijscr.2016.02.035
210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing 
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
further proof of the safety and efﬁcacy of current bioresorbable
vascular scaffolds.
2. Presentation of case
A 59-year-old woman was  admitted for evidence at duplex
ultrasound scan of signiﬁcant in-stent restenosis in the right com-
mon  and internal carotid artery. Her comorbidities were limited to
dyslipidemia. Two years before, a carotid duplex ultrasound scan
had been performed for the work-up of a transient ischemic attack,
disclosing a signiﬁcant stenosis of the ostium of the right inter-
nal carotid artery. She was  then referred to another institution
for carotid angiography, which conﬁrmed the signiﬁcant carotid
stenosis, and underwent during the same procedure carotid angio-
plasty with implantation of an unspeciﬁed 7.0 × 40 mm open-cell
self-expanding stent. Less than 6 months later, control duplex ultra-
sound scan disclosed severe in-stent restenosis, albeit without any
symptom. She was  thus referred to us for appropriate management.
After diagnostic angiography with a 6 French JR4 diagnostic
catheter (VistaBrite, Cordis, Miami, FL, USA) highlighting diffuse
in-stent restenosis involving both the common and internal carotid
artery, a 7 French JR4 guiding catheter was placed in the proximal
right common carotid artery via a 0.035′′ 260 cm Amplatz Super
Stiff J-Tip Emerald guidewire (Cordis) (Fig. 1). Then, we  deployed
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Prior carotid angioplasty for in-stent restenosis. Panel A highlights the baseline angiography with evidence of signiﬁcant in-stent restenosis after implantation of a
7  ﬁlter
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a.0  × 40 mm carotid stent. Panel B shows the deployment of a 7.0 mm Angioguard Rx
redilation. Panel D shows the dilation with a 5.0 × 80 mm Legﬂow drug-eluting bal
nd  antero-posterior (F) views.
n 7.0 mm Angioguard Rx ﬁlter (Cordis), and proceeded to predi-
ation with a 3.0 × 20 mm Trek balloon (Abbott Vascular, Santa
lara, CA, USA), followed by a 5.0 × 40 mm  Aviator Plus balloon
Cordis). Despite the apparently satisfactory angiographic result,
e then opted for further postdilation with a 5.0 × 80 mm Legﬂow
aclitaxel-eluting balloon (Cardionovum, Bonn, Germany) in order
o minimize the risk of recurrent hyperplasia, achieving a good ﬁnal
ngiographic result [10]. Periprocedural antithrombotic therapy
ncluded aspirin, clopidogrel, tiroﬁban and unfractioned heparin,
hereas discharge antiplatelet therapy consisted of lifelong aspirin
nd clopidogrel for 6 months. A control duplex ultrasound scan was
erformed 6 months later. Despite the lack of symptoms, suboc-
lusive recurrent restenosis was found, involving both the carotid
ifurcation and the proximal internal carotid artery. The patient
as thus admitted again to our institution.
As previously, after diagnostic angiography conﬁrming the
ecurrent in-stent restenosis, we deployed a 7 French JR4 guid-
ng catheter and a 7.0 Angioguard Rx ﬁlter (Fig. 2). Predilation was
hen performed with a 4.0 × 40 mm Ryujin Plus balloon (Terumo,
okyo, Japan). Given the drug-eluting balloon failure, the promis-
ng data accrued so far for coronary bioresorbable vascular scaffolds
ven in complex lesions, and our favorable preliminary experience
ith extra-coronary applications of these devices [11,12], we chose
o implant a 3.5 × 28 mm  Absorb bioresorbable vascular scaffold
Abbott Vascular) in the distal common carotid artery and proxi-
al  internal carotid artery, placing the distal edge of the device well
eyond the distal edge of the stent. This choice was mainly based
n our goal of minimizing the risk of subsequent edge restenosis.
e then postdilated the bioresorbable vascular scaffold and theest of the original stent with a 4.5 × 30 mm Aviator Plus balloon,
chieving a satisfactory ﬁnal angiographic result. Periprocedural
ntithrombotic therapy included aspirin, clopidogrel, tiroﬁban and and predilation with a Trek 3.0 × 20 mm balloon. Panel C highlights the result after
Panels E and F highlight the satisfactory ﬁnal angiographic result, in both lateral (E)
unfractioned heparin, whereas discharge antiplatelet therapy was
based on lifelong aspirin and clopidogrel for 12 months.
The patient remained asymptomatic after discharge, and con-
trol duplex ultrasound scan was  performed 6 and 13 months later
(Fig. 3), without any evidence of restenosis. Speciﬁcally, after more
than 12 months since the implantation of the bioresorbable vas-
cular scaffold for recurrent in-stent restenosis and drug-eluting
balloon failure, the metallic stent appeared largely patent, with
faint signs of still incompletely resorbed scaffold struts, all devoid of
signiﬁcant restenosis (peak systolic velocity 120 cm/s, end-diastolic
velocity 40 cm/s) (Fig. 3).
3. Discussion
Thanks to the pioneering efforts of many endovascular spe-
cialists from different disciplines, the introduction of key pieces
of technology such as embolic protection devices and dedicated
carotid stents, and landmark clinical trials, carotid artery stent-
ing is now an established alternative to surgical endarterectomy in
patients with signiﬁcant carotid artery disease [1,2,5]. Much atten-
tion has been paid to the risk of post-procedural or long-term stroke
after stenting, but restenosis is also a clinically relevant complica-
tion.
While carotid in-stent restenosis is relatively uncommon, it may
pose technical challenges, especially when diffuse or subocclusive,
and often recurs after repeat balloon dilation [2]. Accordingly, a
number of approaches and devices have been proposed, including
endarterectomy, cutting balloons, scoring balloons, endovascular
atherectomy, drug-eluting balloons, and drug-eluting stents. No
single one appears clearly best, as neointimal hyperplasia can often
recur unless the stent is altogether removed surgically, a procedure
which is also fraught with signiﬁcant morbidity [2–9,13–18].
CASE  REPORT  –  OPEN  ACCESS
80 A. Giordano et al. / International Journal of Surgery Case Reports 21 (2016) 78–82
Fig. 2. Bioresorbable vascular scaffold implantation. Panel A highlights the baseline angiography disclosing severe in-stent restenosis, with the minimum lumen diameter
localized in the internal carotid artery. Panel B shows the result after deployment of a 7.0 mm Angioguard Rx ﬁlter and predilation with a 4.0 × 40 mm Ryujin Plus balloon. Panel
C  highlights the implantation of the 3.5 × 28 mm absorb bioresorbable vascular scaffold. Panel D shows the angioscopic image after balloon retrieval, with arrows pinpointing
the  bioresorbable vascular scaffold radiopaque markers. Panel E highlights the postdilation with an 4.5 × 30 mm Aviator Plus balloon. Panel F shows the satisfactory ﬁnal
angiographic result.
Fig. 3. Duplex ultrasound scan performed 13 months after bioresorbable vascular scaffold implantation, disclosing a patent stent in the common and internal carotid artery.
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Bioresorbable vascular scaffolds have been recently devised
nd introduced into clinical practice for the treatment of coro-
ary artery disease [19,20]. The most commonly used one is the
bsorb device, which elutes everolimus, thus equaling a drug-
luting stent in terms of hyperplasia inhibition, while relying on
 fully resorbable poly-l-lactic acid (PLLA) platform and polymer
21]. This balloon expandable device has proven non-inferior to
econd-generation drug-eluting stents, and has also been used
uccessfully even in very complex coronary lesions, such as bifur-
ations, chronic total occlusions, and long lesions [21–24]. We have
ecently accrued a substantial expertise in using bioresorbable
ascular scaffolds in both coronary and non-coronary lesions,ent and bioresorbable vascular scaffold contours. Panel B shows the pulsed wave
igniﬁcant in-stent restenosis. BVS = bioresorbable vascular scaffold; ICA = internal
including a preliminary experience with infra-inguinal implan-
tation of these devices for superﬁcial femoral artery disease or
proximal popliteal artery disease [11,12].
Building upon such premises, we chose to implant a biore-
sorbable vascular scaffold to treat a recurrent carotid in-stent
restenosis and drug-eluting balloon failure. Our acute and long-
term results are quite novel, being unprecedented in the literature,
and appear quite favorable. Moreover, they support the con-
cept of considering the individualized off-label use of coronary
bioresorbable vascular scaffolds for selected non-coronary lesions.
More importantly, this clinical vignette highlights the remark-
able effectiveness, versatility and safety of this technology, which
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learly merits further development, with the hope of eventually
eveloping bioresorbable vascular scaffolds explicitly designed for
on-coronary lesions [25,26]. In addition, its low proﬁle ensures
asy deliverability from any access site [27,28].
Despite such rationale and the favorable outcome of our patient,
e do not advocate yet a widespread application of bioresorbable
ascular scaffolds for the management of carotid in-stent resteno-
is. First, the bioresorbable vascular scaffold is more fragile than
 metallic stent and may  lead to a higher risk of embolization in
omparison to a drug-eluting balloon, especially when forcefully
ost-dilated. While this risk remains limited during the proce-
ure if embolic protection is adopted, embolization of relatively
arge strut fragments (150 m)  may  occur before the device is fully
ndothelialized. Second, the balloon expandable design may  be a
istinct disadvantage in the carotid artery, where compression and
rushing of the scaffold may  occur. The presence of an external self-
xpandable stent may  yet provide a certain amount of protection
rom this complication. Our 13-month follow-up based on duplex
ltrasound scan, while adequate for most clinical purposes, cannot
isclose or foresee complications or adverse events due to occur
uch later (e.g., 2 or 3 years after the procedure) and may  have
ower sensitivity than repeat angiography [29]. Nonetheless, this is
nlikely, as after such period of time the scaffold will typically have
lready lost most of its radial support and drug-eluting properties,
nd will typically be completely endothelialized. Finally, whether
nvasive imaging may  be required whenever bioresorbable vascular
caffolds are used remains open to debate [30].
. Conclusion
While awaiting for external validation, this clinical vignette may
xpand the armamentarium of endovascular specialists focusing on
arotid artery disease, while providing further proof of the safety
nd efﬁcacy of current bioresorbable vascular scaffolds.
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